News stories about Keryx Biopharmaceuticals (NASDAQ:KERX) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Keryx Biopharmaceuticals earned a coverage optimism score of 0.23 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.7059324669056 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news articles that may have effected Accern Sentiment Analysis’s analysis:
- Keryx Biopharmaceuticals to Host Conference Call of Third Quarter 2017 Financial Results on Monday, November 6, 2017 (finance.yahoo.com)
- Keep Eyes on Oversold stock: Keryx Biopharmaceuticals, Inc. (KERX) – Wall Street Morning (wallstreetmorning.com)
- Keryx Biopharmaceuticals, Inc. (KERX) is at $5.86 per share and Digirad Corporation (DRAD) is listed at $2.15 – Stocks Gallery (stocksgallery.com)
- Insiders Are Selling – Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) – First News 24 (firstnewspaper24.com)
- Avinger, Inc. (AVGR) registers a price change of 11.01% while Keryx Biopharmaceuticals, Inc. (KERX) finishes with a … – Stocks Gallery (stocksgallery.com)
KERX has been the subject of a number of research reports. Zacks Investment Research cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 8th. Morgan Stanley restated an “equal weight” rating and issued a $7.00 price target (up previously from $4.00) on shares of Keryx Biopharmaceuticals in a research report on Tuesday, July 25th. BidaskClub cut Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 8th. ValuEngine upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, Maxim Group set a $9.00 price target on Keryx Biopharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $7.48.
Shares of Keryx Biopharmaceuticals (KERX) traded up 3.84% during mid-day trading on Monday, reaching $6.22. The company’s stock had a trading volume of 2,334,676 shares. The firm’s market cap is $738.63 million. The firm’s 50-day moving average price is $6.93 and its 200 day moving average price is $6.77. Keryx Biopharmaceuticals has a 12-month low of $4.11 and a 12-month high of $8.38.
Keryx Biopharmaceuticals (NASDAQ:KERX) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.60). Keryx Biopharmaceuticals had a negative net margin of 431.89% and a negative return on equity of 2,902.87%. The business had revenue of $15.10 million during the quarter, compared to analysts’ expectations of $14.51 million. During the same quarter in the prior year, the firm earned ($0.42) EPS. Keryx Biopharmaceuticals’s revenue for the quarter was up 62.4% on a year-over-year basis. On average, analysts expect that Keryx Biopharmaceuticals will post ($1.23) EPS for the current year.
ILLEGAL ACTIVITY WARNING: This report was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.com-unik.info/2017/10/30/keryx-biopharmaceuticals-kerx-earns-daily-media-impact-rating-of-0-23.html.
Keryx Biopharmaceuticals Company Profile
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
What are top analysts saying about Keryx Biopharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Keryx Biopharmaceuticals Inc. and related companies.